Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1373497-18-7
2. D6-dm Hydrobromide
3. Dextromethorphan D6 Hbr Hydrate
4. Dextromethorphan D6 Hydrobromide Monohydrate
5. W9f1od5n5j
6. D6-dm Hydrobromide Monohydrate
7. (1s,9s,10s)-4-(trideuteriomethoxy)-17-(trideuteriomethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrate;hydrobromide
8. Deudextromethorphan Hydrobromide [usan]
9. Deudextromethorphan Hydrobromide Monohydrate
10. Deudextromethorphan Hydrobromide (usan)
11. Unii-w9f1od5n5j
12. Dextromethorphan Hydrobromide, Deuterated (d6)
13. Chembl3989946
14. Morphinan, 3-(methoxy-d3)-17-(methyl-d3)-, (9alpha,13alpha,14alpha)-hydrobromide Monohydrate
15. D11153
16. Q27292496
17. Avp-786 Component Deudextromethorphan Hydrobromide
18. Deudextromethorphan Hydrobromide Component Of Avp-786
19. 3-((2h3)methoxy)-17-((2h3)methyl)-ent-morphinan Hydrobromide Monohydrate
20. Morphinan, 3-(methoxy-d3)-17-(methyl-d3)-, (9.alpha.,13.alpha.,14.alpha.)-hydrobromide Monohydrate
| Molecular Weight | 376.4 g/mol |
|---|---|
| Molecular Formula | C18H28BrNO2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 375.16800 g/mol |
| Monoisotopic Mass | 375.16800 g/mol |
| Topological Polar Surface Area | 13.5 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 370 |
| Isotope Atom Count | 6 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Drugs in Development
Details:
Termination of development of the novel compound AVP-786 (deudextromethorphan HBr), in development for the treatment of agitation associated with dementia due to Alzheimer's.
Lead Product(s): Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area: Neurology Brand Name: AVP-786
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2024
Lead Product(s) : Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Otsuka to Terminate Development of AVP-786
Details : Termination of development of the novel compound AVP-786 (deudextromethorphan HBr), in development for the treatment of agitation associated with dementia due to Alzheimer's.
Product Name : AVP-786
Product Type : Small molecule
Upfront Cash : Not Applicable
May 22, 2024
Details:
AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) is a combinational a CYP2D6 inhibitor. It is being evaluated for the treatment of dementia due to Alzheimer’s disease.
Lead Product(s): Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area: Neurology Brand Name: AVP-786
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Lead Product(s) : Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Otsuka Announces Phase 3 Results of AVP-786 for Agitation Associated with Alzheimer’s
Details : AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) is a combinational a CYP2D6 inhibitor. It is being evaluated for the treatment of dementia due to Alzheimer’s disease.
Product Name : AVP-786
Product Type : Small molecule
Upfront Cash : Not Applicable
February 12, 2024
Details:
Avanir and Otsuka have always shared a deep commitment to advancing solutions that improve the lives of patients by Nuedexta (dextromethorphan hydrobromide and quinidine sulfate).
Lead Product(s): Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area: Neurology Brand Name: AVP-786
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Otsuka America Pharmaceutical, Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 24, 2022
Lead Product(s) : Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Otsuka America Pharmaceutical, Inc.
Deal Size : Undisclosed
Deal Type : Merger
Details : Avanir and Otsuka have always shared a deep commitment to advancing solutions that improve the lives of patients by Nuedexta (dextromethorphan hydrobromide and quinidine sulfate).
Product Name : AVP-786
Product Type : Small molecule
Upfront Cash : Undisclosed
October 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
53
PharmaCompass offers a list of Deudextromethorphan Hydrobromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Deudextromethorphan Hydrobromide manufacturer or Deudextromethorphan Hydrobromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Deudextromethorphan Hydrobromide manufacturer or Deudextromethorphan Hydrobromide supplier.
PharmaCompass also assists you with knowing the Deudextromethorphan Hydrobromide API Price utilized in the formulation of products. Deudextromethorphan Hydrobromide API Price is not always fixed or binding as the Deudextromethorphan Hydrobromide Price is obtained through a variety of data sources. The Deudextromethorphan Hydrobromide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Deudextromethorphan Hydrobromide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deudextromethorphan Hydrobromide, including repackagers and relabelers. The FDA regulates Deudextromethorphan Hydrobromide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deudextromethorphan Hydrobromide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Deudextromethorphan Hydrobromide supplier is an individual or a company that provides Deudextromethorphan Hydrobromide active pharmaceutical ingredient (API) or Deudextromethorphan Hydrobromide finished formulations upon request. The Deudextromethorphan Hydrobromide suppliers may include Deudextromethorphan Hydrobromide API manufacturers, exporters, distributors and traders.
Deudextromethorphan Hydrobromide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deudextromethorphan Hydrobromide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Deudextromethorphan Hydrobromide GMP manufacturer or Deudextromethorphan Hydrobromide GMP API supplier for your needs.
A Deudextromethorphan Hydrobromide CoA (Certificate of Analysis) is a formal document that attests to Deudextromethorphan Hydrobromide's compliance with Deudextromethorphan Hydrobromide specifications and serves as a tool for batch-level quality control.
Deudextromethorphan Hydrobromide CoA mostly includes findings from lab analyses of a specific batch. For each Deudextromethorphan Hydrobromide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deudextromethorphan Hydrobromide may be tested according to a variety of international standards, such as European Pharmacopoeia (Deudextromethorphan Hydrobromide EP), Deudextromethorphan Hydrobromide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deudextromethorphan Hydrobromide USP).
